---
title: 'Regulatory Daily Summary: What Happened on October 20, 2026'
headline: MFN deadline passes for mid-sized drugmakers
description: Companies without agreements could face tariffs on imported goods.
url: https://thebench.bio/news/regulatory/2026-10-20
topic: regulatory
date: '2026-10-20'
covers:
- '2026-10-20'
date_published: '2026-10-20T12:02:44Z'
date_modified: '2026-10-20T12:02:44Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on October 20, 2026

**MFN deadline passes for mid-sized drugmakers**

Companies without agreements could face tariffs on imported goods.

## Today in brief

Mid-sized drugmakers missed the deadline to reach Most-Favored Nation agreements with the administration, leaving non-signatories potentially exposed to tariffs on imported goods. [1]

## Also worth knowing

- The initiative aims to lower U.S. drug prices and encourage domestic manufacturing. [1]

## Also published

- [Renewal Season is Here! FY 2027 Device Establishment Registration and Listing](<https://www.thefdalawblog.com/2026/10/renewal-season-is-here-fy-2027-device-establishment-registration-and-listing/?utm_source=rss&utm_medium=rss&utm_campaign=renewal-season-is-here-fy-2027-device-establishment-registration-and-listing>), FDA Law Blog

## Sources

1. [How MFN Deals May Impact Future Decisions](<https://www.pharmexec.com/view/how-mfn-deals-may-impact-future-decisions>), Pharmaceutical Executive, 2026-10-20

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmexec.com/view/how-mfn-deals-may-impact-future-decisions>